News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
Editorial Board
For Authors
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice Between the LinesContemporary ConceptsJournalOncViewPodcastsReadout 360Insights from Experts at Mayo Clinic on Translating Evidence to Clinical PracticeOptimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid LeukemiaBrain CancerBreast CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHematologyLeukemiaLung CancerLymphomaPediatric CancersSkin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
Editorial Board
For Authors
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Melanoma
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Melanoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Phase 3 INTERLINK-1 Trial of Monalizumab Plus Cetuximab in Recurrent or Metastatic HNSCC Discontinued

August 3, 2022
Ariana Pelosci
Article

Findings from the planned futility interim analysis of the phase 3 INTERLINK-1 trial has led to the study’s termination after monalizumab and cetuximab did not meet efficacy end points in recurrent or metastatic squamous cell carcinoma in the head and neck.

The phase 3 INTERLINK-1 trial’s (NCT04590963) planned futility interim analysis, assessing monalizumab plus cetuximab (Erbitux) vs cetuximab alone for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have previously been treated with platinum-based chemotherapy and PD-L1 inhibitors, indicated that the trial’s primary end points were missed, according to a press release from Innate Pharmaceuticals. This has led to the trial’s termination.

The recommendation came from an independent data monitoring committee, leading to AstraZeneca informing Innate of the trial’s discontinuation. No new safety findings were reported, and additional data will be shared, AstraZeneca stated.

“The INTERLINK-1 phase 3 study was intended to further evaluate a novel immunotherapy regimen following the promising signals observed in a non-randomized phase 1b/2 study of head and neck cancer. While we are disappointed with the outcome of this study, the findings are certain to advance our understanding of the role of immunotherapy in this setting,” Mondher Mahjoubi, chief executive officer at Innate Pharma, said in the press release.

Monalizumab is a first-in-class immune checkpoint inhibitor that targets the NKG2A receptors that are expressed on tumor-infiltrating cytotoxic CD8-positive T cells and natural killer cells. Monalizumab is also being studied in the phase 3 PACIFIC-9 trial (NCT052218490) in combination with durvalumab (Imfinzi) or oleclumab (MEDI9447) for those with unresectable stage III non–small cell lung cancer who have not progressed on platinum-based concurrent chemoradiation therapy.

Investigators intended to enroll about 600 patients with recurrent or metastatic HNSCCC who have previously been treated with platinum-based chemotherapy and PD-L1 inhibitors. The primary end point was overall survival (OS) for those who with human papillomavirus–unrelated disease. The secondary end points were OS in all patients, progression-free survival, overall response rate, duration of response, safety, and quality of life.

To be included in this trial, patients were required to be 18 years or older with recurrent or metastatic disease that had progressed on or after previous treatment and was not amenable to curative therapy. Patients must have had a prior platinum failure, received 1 or 2 prior systemic regimens, have measurable disease, recent tumor tissue for biomarker testing, and World Health Organization/ECOG performance status of 0 or 1.

Exclusion criteria included having head and neck cancer in a primary anatomic location not specified in the inclusion criteria, receipt of prior cetuximab therapy, active or prior documented autoimmune or inflammatory disorders, diverticulitis, or any concurrent anticancer treatment besides hormonal therapy for non-cancer-related conditions.

“We are disappointed by this outcome and what it means for patients. We would like to thank the patients, investigators, and healthcare professionals who dedicated their time and expertise to this trial, which has advanced our understanding of metastatic head and neck cancer. We continue to explore the impact of monalizumab in patients with [NSCLC] across different trials, including the phase 3 PACIFIC-9 trial,” Susan Galbraith, executive vice president of Oncology Research & Development at AstraZeneca, concluded.

Reference

Innate Pharma provides update on AstraZeneca-sponsored INTERLINK-1 phase 3 study. News Release. August 1, 2022. Accessed August 3, 2022. https://yhoo.it/3oOARub

Related Videos
head and neck cancer
head and neck cancer
head and neck cancer
head and neck cancer
head and neck cancer
Related Content
Advertisement

After observing a prevalence of thyroid cancer among transgender female patients through clinical observation, a study was prompted by clinicians in order to determine if this is an issue in a larger population.

Thyroid Cancer Rates Are Higher Among Transgender Female Veterans

October 29th 2023
Article

Study shows a high prevalence of thyroid cancer in transgender female patients.


David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

September 15th 2017
Podcast

In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.


Findings from a phase 2 trial also show that there is no progression-free survival or overall survival benefit with lapatinib plus chemoradiotherapy in patients with non-human papillomavirus–related head and neck cancer.

Lapatinib Does Not Improve CRT Outcomes in Non-HPV Head and Neck Carcinoma

October 27th 2023
Article

Findings from a phase 2 trial also show that there is no progression-free survival or overall survival benefit with lapatinib plus chemoradiotherapy in patients with non-human papillomavirus–related head and neck cancer.


A yoga intervention program in patients with head and neck cancer appears to correlate with significantly fewer feeding tube placements compared with those receiving usual care.

Yoga May Reduce Physical Decline in HNC Population Receiving Radiotherapy

October 24th 2023
Article

A yoga intervention program in patients with head and neck cancer appears to correlate with significantly fewer feeding tube placements compared with those receiving usual care.


Sacituzumab Govitecan Displays Antitumor Activity in Advanced HNSCC

Sacituzumab Govitecan Displays Antitumor Activity in Advanced HNSCC

October 21st 2023
Article

Sacituzumab govitecan showed anti-tumor activity in patients with pretreated metastatic or locally recurrent head and neck squamous cell carcinoma.


Investigators will assess the safety and pharmacodynamics of ALE.C04 in patients with CLDN1-positive head and neck squamous cell carcinoma as part of a phase 1/2 clinical trial.

FDA Grants Fast Track Designation to ALE.C04 in CLDN1+ HNSCC

August 24th 2023
Article

Investigators will assess the safety and pharmacodynamics of ALE.C04 in patients with CLDN1-positive head and neck squamous cell carcinoma as part of a phase 1/2 clinical trial.

Related Content
Advertisement

After observing a prevalence of thyroid cancer among transgender female patients through clinical observation, a study was prompted by clinicians in order to determine if this is an issue in a larger population.

Thyroid Cancer Rates Are Higher Among Transgender Female Veterans

October 29th 2023
Article

Study shows a high prevalence of thyroid cancer in transgender female patients.


David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

September 15th 2017
Podcast

In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.


Findings from a phase 2 trial also show that there is no progression-free survival or overall survival benefit with lapatinib plus chemoradiotherapy in patients with non-human papillomavirus–related head and neck cancer.

Lapatinib Does Not Improve CRT Outcomes in Non-HPV Head and Neck Carcinoma

October 27th 2023
Article

Findings from a phase 2 trial also show that there is no progression-free survival or overall survival benefit with lapatinib plus chemoradiotherapy in patients with non-human papillomavirus–related head and neck cancer.


A yoga intervention program in patients with head and neck cancer appears to correlate with significantly fewer feeding tube placements compared with those receiving usual care.

Yoga May Reduce Physical Decline in HNC Population Receiving Radiotherapy

October 24th 2023
Article

A yoga intervention program in patients with head and neck cancer appears to correlate with significantly fewer feeding tube placements compared with those receiving usual care.


Sacituzumab Govitecan Displays Antitumor Activity in Advanced HNSCC

Sacituzumab Govitecan Displays Antitumor Activity in Advanced HNSCC

October 21st 2023
Article

Sacituzumab govitecan showed anti-tumor activity in patients with pretreated metastatic or locally recurrent head and neck squamous cell carcinoma.


Investigators will assess the safety and pharmacodynamics of ALE.C04 in patients with CLDN1-positive head and neck squamous cell carcinoma as part of a phase 1/2 clinical trial.

FDA Grants Fast Track Designation to ALE.C04 in CLDN1+ HNSCC

August 24th 2023
Article

Investigators will assess the safety and pharmacodynamics of ALE.C04 in patients with CLDN1-positive head and neck squamous cell carcinoma as part of a phase 1/2 clinical trial.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.